Philips completes regional informatics project in Southern Denmark » 05:2610/2610/26/20
Philips announced the…
Philips announced the completion of a regional informatics project that consolidates radiology and nuclear medicine imaging data. The Region of Southern Denmark now has a single system for storing, retrieving and viewing clinical images across all the locations and specialties in its healthcare system. The Region of Southern Denmark health service encompasses four hospital groups with a total of 12 hospitals that serve a population of over 1.2M people living on both on the mainland and the region's many islands. The unified imaging ecosystem will serve all of the region's approximately 300 radiologists and nuclear medicine specialists, performing 1.5M exams yearly. The related images are now accessible to the over 5,000 clinicians in the region.
Philips, SGH to establish pathology center of excellence » 05:2510/2310/23/20
Philips announced a…
Philips announced a collaboration with Singapore General Hospital, or SGH, to establish the Singapore General Hospital Digital and Computational Pathology Center of Excellence. The SGH Center of Excellence aims to advance pathology practice by implementing a fully digital histopathology workflow and deploying Artificial Intelligence, or AI, to increase productivity and enhance patient care. Located within SGH's Division of Pathology, the Center of Excellence aims to establish ASEAN's first fully digitized histopathology laboratory by expanding its digital pathology capabilities for primary diagnosis, training, and R&D with the Philips IntelliSite Pathology Solution. Both SGH and Philips will also work closely on other diverse areas, including streamlining of the histopathology laboratory's digital workflow.
|Over a week ago|
FDA Patient Engagement Advisory Committee to hold a virtual meeting » 09:4210/2210/22/20
The Committee discusses…
The Committee discusses and makes recommendations on the topic, "Artificial Intelligence (AI) and Machine Learning (ML) in Medical Devices" with Pat Baird, Head of Global Software Standards, at Philips in a virtual meeting being held on October 22 at 10 am. Webcast Link
Philips price target lowered to EUR 52 from EUR 54 at Deutsche Bank » 11:2210/2110/21/20
Deutsche Bank analyst…
Deutsche Bank analyst Falko Friedrichs lowered the firm's price target on Philips to EUR 52 from EUR 54 and keeps a Buy rating on the shares.
Philips, SimonMed Imaging partner to deploy diagnostic imaging technology » 09:0310/2110/21/20
Royal Philips announced…
Royal Philips announced that SimonMed Imaging will bring the most advanced 3T MRI Philips technology to its centers of excellence across the U.S. The first MR systems, placed in California, Arizona, Illinois and Colorado, will feature software and services to enhance diagnoses ranging from brain injuries, liver and cardiac disease, to orthopedic injuries. Philips and SimonMed are also collaborating to further enhance the patient experience and speed in diagnostic imaging.
Philips, Marienhospital Stuttgart sign 10-year agreement to expand hospital care » 05:3510/2110/21/20
Philips and Marienhospital Stuttgart signed a 10-year strategic partnership agreement to expand medicine at the hospital and provide integrated patient care. The project will include renewal and ongoing development of the hospital's diagnostic imaging equipment and associated IT systems, digitization of its pathology department, and enhancement of the hospital's emergency medicine capabilities. Rather than treating each of these improvement areas as a separate exercise, Philips and Marienhospital Stuttgart will integrate them into connected patient care and optimized efficiency solutions. This will involve analysis of the hospital's current treatment structures and pathways to enhance the overall quality of the hospital's structures, processes and results, while also identifying potential cost savings. By jointly developing needs-based technology solutions, Marienhospital Stuttgart will be able to better plan its costs and ensure investment security in all areas.
Philips price target raised to EUR 50 from EUR 49 at UBS » 13:3110/2010/20/20
UBS analyst Matthew…
UBS analyst Matthew Taylor raised the firm's price target on Philips to EUR 50 from EUR 49 and keeps a Buy rating on the shares.
Philips price target raised to EUR 39.40 from EUR 38.60 at JPMorgan » 13:1610/2010/20/20
JPMorgan analyst David…
JPMorgan analyst David Adlington raised the firm's price target on Philips to EUR 39.40 from EUR 38.60 and keeps a Neutral rating on the shares.
Fly Intel: Pre-market Movers » 09:2110/1910/19/20
FLDM, MD, AEL, HAL, PHG, CXO, COP, SMMC, SGH, CREE, OSUR, LOOP
Check out this morning's…
Philips sees free cash flow above EUR 2B by 2025 » 05:1010/1910/19/20
Sees an acceleration of…
Sees an acceleration of the average annual comparable sales growth to 5%-6%, with all business segments within this range. For 2021, Philips' current view is that Group comparable sales will deliver low-single-digit growth, driven by solid growth in Diagnosis & Treatment and Personal Health, partly offset by lower Connected Care sales. Sees an adjusted EBITA margin improvement of 60-80 basis points on average annually from 2021, reaching the high teens for the group by 2025. Sees organic return on invested capital, or ROIC, of mid-to-high teens by 2025. "We are excited to continue our journey to create further value by improving growth and profitability, while recognizing that we are in very uncertain times, and with the assumption that the world economy will return to growth next year," said Frans van Houten. "The new targets are underpinned by our strategic imperatives to further improve customer and operational excellence, boost growth in our core businesses through geographical expansion and more customer partnerships, and win with innovative solutions along the health continuum. Our strategy to transform care along the health continuum - from healthy living and prevention to diagnosis and treatment, telehealth and home care - strongly resonates with customers and has been further validated during the COVID-19 pandemic."